Clinical Trials Insight: 700023506
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2009
At a glance
- Drugs ABT 107 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 31 Mar 2009 Status changed from recruiting to completed. Abbott has been evaluating ABT 107 under a license agreement with NeuroSearch. Based on results, Abbott and NeuroSearch have decided not to pursue development of the compound at this time.
- 29 Nov 2007 Neurosearch report that the phase I programme is progressing as scheduled.
- 31 May 2007 New trial record.